A brand new injectable facility of Aurobindo Pharma’s step-down subsidiary Eugia US Manufacturing LLC in New Jersey, U.S., has been issued 10 observations by the USA Meals and Drug Administration (U.S. FDA) after a pre-approval inspection.
“The inspection closed with 10 observations. The observations are procedural in nature and might be responded to throughout the stipulated time. The plant is but to start out business operations,” the drugmaker mentioned in a submitting on Sunday. The U.S. FDA had inspected the ability from December 11-22.